[HTML][HTML] Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes
LC Villaruz, MA Socinski - European Journal of Cancer, 2016 - Elsevier
Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with
carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) …
carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) …
Efficacy and Safety of Nanoadministration in the Treatment of Non‐Small‐Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta‐Analysis
R Han, Y Guan, M Li, A Xu, D Wu, P Li… - Journal of …, 2022 - Wiley Online Library
Purpose. The purpose of this study was to evaluate the efficacy and safety of a nanodrug
delivery regimen compared with conventional drug administration for the treatment of lung …
delivery regimen compared with conventional drug administration for the treatment of lung …
[HTML][HTML] Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: analysis of safety and …
V Hirsh, A Ko, R Pilot, MF Renschler, MA Socinski - Clinical Lung Cancer, 2016 - Elsevier
Purpose To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-
P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with …
P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with …
nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
CJ Langer, A Gajra, C Gridelli, K Konduri… - Frontiers in …, 2021 - frontiersin.org
Introduction Despite improvements in the treatment of advanced non-small cell lung cancer
(NSCLC), certain patient populations remain underrepresented in clinical trials. Many …
(NSCLC), certain patient populations remain underrepresented in clinical trials. Many …